Expertise in
1
conditions

Dr. Rishi Kakar

Psychiatry
Compass Health Systems P.A.
1065 NE 125th St Ste 206, 
North Miami, FL 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Expertise in
1
conditions
Compass Health Systems P.A.
1065 NE 125th St Ste 206, 
North Miami, FL 

Overview

Rishi Kakar is a Psychiatrist practicing medicine in North Miami, Florida.

Dr. Kakar is highly rated in 1 condition, according to our data. His clinical expertise encompasses Schizophrenia, Schizoaffective Disorder, Major Depression, and Bipolar Disorder (BPD).

He is actively involved in clinical research, co-authoring 12 peer reviewed articles and participating in 14 clinical trials. Dr. Kakar is currently accepting new patients.

Specialties

Psychiatry

Licenses

Psychiatry & Neurology in FL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

Compass Health Systems P.A.
1065 NE 125th St Ste 206, North Miami, FL 33161
Other Locations
Office
7481 W Oakland Park Blvd Ste 205, Tamarac, FL 33319

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
Enrollment Status: Recruiting
Publish Date: June 15, 2026
Intervention Type: Device
Study Phase: Not Applicable
A Phase 2a, Randomized, Double-blind, Placebo-controlled Proof of Concept Study to Evaluate the Effects of Oral BTRX-335140 (NMRA-335140) Versus Placebo in Subjects With Major Depressive Disorder
A Phase 2a, Randomized, Double-blind, Placebo-controlled Proof of Concept Study to Evaluate the Effects of Oral BTRX-335140 (NMRA-335140) Versus Placebo in Subjects With Major Depressive Disorder
Enrollment Status: Completed
Publish Date: May 29, 2025
Intervention Type: Drug
Study Drug: BTRX-335140
Study Phase: Phase 2
The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes
The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes
Enrollment Status: Terminated
Publish Date: December 20, 2024
A Double-blind, Oral, Multiple-dose, Parallel, Randomized Study to Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients
A Double-blind, Oral, Multiple-dose, Parallel, Randomized Study to Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients
Enrollment Status: Completed
Publish Date: September 23, 2024
Intervention Type: Drug
Study Drug: Endoxifen
Study Phase: Phase 3
A Randomized, Single-Dose, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetic Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
A Randomized, Single-Dose, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetic Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
Enrollment Status: Completed
Publish Date: March 19, 2024
Intervention Type: Drug
Study Phase: Phase 1
Phase 2a Multicenter Randomized Double-Blind Placebo-Controlled Study to Assess the Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing of REL-1017 as Adjunctive Therapy in the Treatment of Pts Diagnosed With MDD
Phase 2a Multicenter Randomized Double-Blind Placebo-Controlled Study to Assess the Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing of REL-1017 as Adjunctive Therapy in the Treatment of Pts Diagnosed With MDD
Enrollment Status: Completed
Publish Date: November 01, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Study to Evaluate the PK Profiles of LY03010 and Relative Bioavailability at Steady-state of LY03010 Versus INVEGA SUSTENNA in Schizophrenia Patients
A Study to Evaluate the PK Profiles of LY03010 and Relative Bioavailability at Steady-state of LY03010 Versus INVEGA SUSTENNA in Schizophrenia Patients
Enrollment Status: Completed
Publish Date: April 25, 2023
Intervention Type: Drug
Study Drugs: LY03010, Sustenna
Study Phase: Phase 1
A Single Arm, Adaptive Design, Pivotal Trial to Assess the Efficacy of AKL-T01, a Novel Digital Intervention Designed to Improve Attention, in Adults Diagnosed With Attention Deficit Hyperactive Disorder
A Single Arm, Adaptive Design, Pivotal Trial to Assess the Efficacy of AKL-T01, a Novel Digital Intervention Designed to Improve Attention, in Adults Diagnosed With Attention Deficit Hyperactive Disorder
Enrollment Status: Completed
Publish Date: February 28, 2023
Intervention Type: Other
Study Phase: Not Applicable
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Enriched-Enrollment Withdrawal, Multicenter Study to Evaluate the Efficacy and Safety of a Long-Acting Subcutaneous Injectable Depot of Buprenorphine (CAM2038) in Subjects With Moderate to Severe Chronic Low Back Pain Currently Treated With Daily Opioids
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Enriched-Enrollment Withdrawal, Multicenter Study to Evaluate the Efficacy and Safety of a Long-Acting Subcutaneous Injectable Depot of Buprenorphine (CAM2038) in Subjects With Moderate to Severe Chronic Low Back Pain Currently Treated With Daily Opioids
Enrollment Status: Completed
Publish Date: October 15, 2021
Intervention Type: Drug, Other
Study Phase: Phase 3
A Phase IIIb Multi-Center, Open-Label, Mirror-Image, Trial in Adult Subjects With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®
A Phase IIIb Multi-Center, Open-Label, Mirror-Image, Trial in Adult Subjects With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®
Enrollment Status: Terminated
Publish Date: September 05, 2021
Intervention Type: Combination product
Study Drug: ABILIFY MYCITE
Study Phase: Phase 3
View 9 Less Clinical Trials

12 Total Publications

Antipsychotic Efficacy and Safety of LB-102 in the Treatment of Adults With Acute Schizophrenia: A Randomized Clinical Trial.
Antipsychotic Efficacy and Safety of LB-102 in the Treatment of Adults With Acute Schizophrenia: A Randomized Clinical Trial.
Journal: JAMA psychiatry
Published: April 22, 2026
Similar Doctors
Expertise in
11
conditions
Expertise in
11
conditions
Referral may be required

Compass Colorado Healthcare Systems Inc.

1065 NE 125th St, 
North Miami, FL 
 (0.3 miles away)
888-852-6672
Languages Spoken:
English, Bengali, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Tanveer Sobhan is a Psychiatrist practicing medicine in North Miami, Florida. Dr. Sobhan is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Seasonal Affective Disorder (SAD), Major Depression, Schizoaffective Disorder, and Bipolar Disorder (BPD). Dr. Sobhan is currently accepting new patients.

Expertise in
14
conditions
Expertise in
14
conditions
Referral may be required

Compass Colorado Healthcare Systems Inc.

1065 NE 125th St, 
North Miami, FL 
 (0.3 miles away)
888-852-6672
Languages Spoken:
English, French, Hebrew, Spanish, Yiddish
See accepted insurances
Accepting New Patients
Offers Telehealth

Yakov Greenstein is a Psychiatrist practicing medicine in North Miami, Florida. Dr. Greenstein is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Major Depression, Bipolar Disorder (BPD), Seasonal Affective Disorder (SAD), and Schizoaffective Disorder. Dr. Greenstein is currently accepting new patients.

Expertise in
6
conditions
Expertise in
6
conditions
Referral may be required

Miami Beach Community Health Center Inc.

8260 NE 2nd Ave, 
Miami, FL 
 (3.0 miles away)
954-392-6099
Languages Spoken:
English, French, Haitian, Haitian Creole
See accepted insurances
Accepting New Patients
Offers Telehealth

Patrick Pinchinat is a Psychiatrist practicing medicine in Miami, Florida. Dr. Pinchinat is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Schizophrenia, Schizoaffective Disorder, Major Depression, and Bipolar Disorder (BPD). Dr. Pinchinat is currently accepting new patients.

Frequently Asked Questions about Dr. Rishi Kakar

How do I make an appointment with Dr. Rishi Kakar?

You can book an appointment with Dr. Rishi Kakar by calling their office at 888-852-6672. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Rishi Kakar a top-rated expert for Schizophrenia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Rishi Kakar is classified as an Advanced expert for Schizophrenia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Rishi Kakar specialize in?

While Dr. Rishi Kakar is a Psychiatry, they have specific expertise in Schizophrenia, Schizoaffective Disorder, and Major Depression. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Psychiatry.

Does Dr. Rishi Kakar participate in research or clinical trials?

Yes. Dr. Rishi Kakar has published 12 articles and abstracts on conditions like Schizophrenia. You can view a list of Dr. Rishi Kakar's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Rishi Kakar accept my insurance?

Dr. Rishi Kakar accepts most major insurance plans, including Cigna and Florida Blue. We recommend calling the office directly at 888-852-6672 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kakar's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile